Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2015

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

(1) , (1) , (2) , (3) , , (4, 5) , (6) , (2) , (7) , (8) , (9) , , , (10) , (11) , , , (12) , (13) , (14, 15) , (16) , , , , (5) , (17) , (18) ,
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Nelly Robillard
  • Function : Author
Laurent Garderet
Lionel Karlin
  • Function : Author
Frederique Orsini-Piocelle
  • Function : Author
Bruno Royer
  • Function : Author
Paul G. Richardson
  • Function : Author
Kenneth C. Anderson
  • Function : Author
Malek Faham
  • Function : Author
Philippe Moreau
Michel Attal
  • Function : Author
  • PersonId : 944589
Nikhil C Munshi
  • Function : Author

Abstract

57th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 05-08, 2015
Not file

Dates and versions

hal-01300806 , version 1 (11-04-2016)

Identifiers

  • HAL Id : hal-01300806 , version 1

Cite

Herve Avet-Loiseau, Jill Corre, Valérie Lauwers-Cances, Marie-Lorraine Chretien, Nelly Robillard, et al.. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. Blood, 2015, 126 (23), pp.191. ⟨hal-01300806⟩
239 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More